

Risk Factors of Coronary In–Stent Restenosis in Drug-Eluting Stent: A Systematic Review and Meta-Analysis

Hotmauli Siahaan^{1*}, Hari Basuki Notobroto², Yudi Her Oktaviono³,
Paulus Parholong Siahaan⁴, David Setyo Budi⁴, Rizky Novita Anjaswanti⁵

¹Doctoral Program of Public Health, Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia.

²Department of Epidemiology, Biostatistics, Population Studies and Health Promotion, Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia.

³Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

⁴Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

⁵Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia.

***Corresponding Author:**

Hotmauli Siahaan, MD. Faculty of Public Health, Universitas Airlangga, Campus C, Mulyorejo, Surabaya 60115, Indonesia. Email: hotmauli.siahaan-2023@fkm.unair.ac.id

ABSTRACT

Background: In-stent restenosis (ISR) is an event of coronary atherosclerosis re-budling following the stent implantation in percutaneous coronary intervention. The events of ISR have been significantly reduced since the introduction of drug-eluting stents. However, ISR could still occur, and factors affecting the incident have not yet been discovered. This study aims to evaluate the risk factors of coronary in-stent restenosis in drug-eluting stents. **Methods:** Studies on the factors and risks of ISR in patients with drug-eluting stents were systematically searched in databases (PubMed, ScienceDirect, Springer, Google Scholar, and ProQuest) on September 20th, 2023. The odds ratio (OR) and mean difference (MD) were analyzed using Review Manager 5.4. **Results:** Diabetes mellitus (OR 1.73 [95%CI 1.56, 1.91] $p < 0.00001$) and smoking (OR 1.24 [95%CI 1.13, 1.36] $p < 0.0001$) are the patients' clinical characteristics that are associated with ISR in DES. It is closely related to the contribution of diabetes mellitus in promoting platelet adhesion and smoking in enhancing intimal hyperplasia. As in the angiography characteristics, stent lesion at LAD (OR 1.20 [95%CI 1.07, 1.35] $p = 0.002$) and stent length (MD 3.61 [95%CI 1.81, 5.42] $p < 0.0001$) are correlated with the events of ISR. Every millimeter excess of stent length significantly increases the risk of ISR. Therefore, reducing the excess stent length may contribute to the reduced risk of ISR in DES. **Conclusion:** The identification of risk factors contributing to ISR in DES may help cardiologists modify the attributable factors and prevent the occurrence of ISR.

Keywords: Drug-eluting stents, Meta-analysis, Risk factor ISR, Systematic review.

INTRODUCTION

Percutaneous coronary intervention (PCI) has become one of the effective methods for the treatment of coronary heart disease (CHD). However, it is easy to have in-stent restenosis (ISR), even cardiovascular events after PCI, which affects the therapeutic effects. In-stent

restenosis is a corollary of the improved durability of modern-day coronary inter. After performing percutaneous coronary intervention (PCI), patients are still at risk of developing new stenosis, such as intra-stent restenosis (ISR).¹ The widespread application of new anticoagulants and drug-eluting stents has

significantly decreased the incidence of coronary ISR. Nevertheless, large-scale clinical trials have confirmed that a 5% probability of restenosis exists despite the use of drug-eluting stents.²

The first and especially second-generation drug-eluting stents (DES) were specifically designed to reduce hyperproliferation within stents as a mechanism to overcome the high rate of ISR.³ Nevertheless, the prevalence of ISR is estimated to vary from 3 to 20% in the current DES era, depending on coronary anatomy, and patient- and procedure-related factors.³ This suggests that the type of stent is only one factor to consider when searching for additional promoters of ISR. The results of previous research concluded that the factors associated with ISR after PCI have not been clearly defined. In previous studies, several risk factors for ISR have been found, but not much research data on risk factors for ISR in drug-eluting stents (DES). For this reason, we systematically review the latest evidence to detect the risk factors of in-stent restenosis with drug-eluting stents (DES).

METHODS

This meta-analysis is conducted based on PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) 2020 guidelines. This study had been registered on the PROSPERO database (CRD42023465249).

Eligibility Criteria

Studies were selected based on inclusion criteria, which are: (1) observational study with human subjects, (2) investigated the association between risk factors and ISR after stent implantation (DES), (3) ISR was defined as $\geq 50\%$ diameter stenosis of the culprit lesion by quantitative coronary analysis. The exclusion criteria were: (1) CAD without implantation stent, (2) RCT study. Two independent reviewers screened for the included studies (PS and PBTS). Our senior reviewer (HS) made the final decision when there were differences in the screening results.

Search Strategy and Selection of Studied

Electronic databases include PubMed, ScienceDirect, Springer, Google Scholar, and

Proquest. The search terms have diabetes mellitus, ISR, in-stent restenosis, PCI, risk factor, and drug-eluting stent. Databases were searched using terms (('risk factors')) AND (('drug eluting stent')) AND (('in stent restenosis')) on September 20th, 2023. Newcastle-Ottawa Scale was used to evaluate the risk of bias for each study independently, with each bias assessment consisting of the selection of the study groups; the comparability of the groups; and the ascertainment of either the exposure or outcome of interest, with the assessment of good, fair, and low quality of a study.

Data Extraction

The following data: age, patient's status of hypertension, diabetes mellitus, smoking, dyslipidemia, and family history of CAD, and the paramount data of lesion at LAD, lesion at LCX, lesion at RCA, stent diameter, and stent length, each representing ISR and Non-ISR patients were collected and recorded in a formatted table.

Statistical Analysis

The software Review Manager 5.4 was used to conduct statistical analyses, dichotomous data (risk ratio and odds ratio) used Mantel-Haenszel statistical method for hypertension, diabetes mellitus, smoking, dyslipidemia, and family history of CAD, and the paramount data of lesion at LAD, lesion at LCX, lesion at RCA, and continuous data (mean difference) used inverse variance statistical method for stent length and diameter. Heterogeneity was analyzed using the DerSimonian and Laird random-effect model.

Sensitivity analysis should also be done, by using the leave-one-out approach to detect study outliers and changes in heterogeneity (I²), with I² values of 0-50% representing low heterogeneity, 50-75% representing moderate heterogeneity, and 76-100% representing substantial heterogeneity. The data analysis employed either the fixed or the random effect model. All statistical analysis with a p-value < 0.05 was considered statistically significant. Leave-one-out sensitivity analysis was conducted to find the source of statistical heterogeneity and demonstrate how each study affected the overall result.




Figure 1. The study selection process in the PRISMA diagram

RESULTS

Characteristics of Studies

Among 12,526 studies gathered from databases, 28 articles were included.⁴⁻³¹ The risk of bias from 26 articles was assessed to be good, while the other 2 studies were fair. This study involved a total of 12,559 patients, where 2,701 patients developed ISR and the rest 9,858 were


non-ISR patients as controls. Most of the studies originated from China, while there was one study from Türkiye, one study from Japan, and the rest one study was from Italy. Data were collected from patients from 2004 to 2020. Moreover, the quality of the included studies was assessed using the Newcastle-Ottawa Scale and summarized in Supplementary Materials (Table S2).

Table 1. Characteristics of subjects.


No	Outcomes	No of Studies	Type of TE	TE (95% CI)	P	I ²	P for I ²
1.	Hypertension	26	OR	1.23 (1.03, 1.47)	0.02	61%	< 0.0001
2.	Diabetes Mellitus	25	OR	1.73 (1.56, 1.91)	< 0.00001	43%	0.01
3.	Smoking	27	OR	1.24 (1.13, 1.36)	< 0.0001	33%	0.05
4.	Family history of CAD	10	OR	1.27 (1.02, 1.58)	0.03	0%	0.77
5.	Dyslipidemia	19	OR	1.12 (0.89, 1.41)	0.33	71%	<0.00001

26 articles discuss hypertension and the incidence of ISR. The results of the study stated that hypertension showed a significant relationship with the incidence of ISR (OR 1.23; CI 95% 1.03-1.47; I2 61%; $p < 0.0001$). However, the prevalence of hypertension between ISR and non-ISR was 2402 versus 9922, which shows an increased rate of restenosis in hypertension. In the diabetes mellitus variable, 25 articles discuss the relationship between diabetes mellitus and ISR incidence. This study found a significant correlation between diabetes mellitus and ISR events (OR 1.73; 95% CI 1.56-1.91; I2 43%;


$p < 0.00001$). The research we have conducted from 27 articles states that there is a significant correlation between smoking and the incidence of ISR (OR 1.24; 95% CI 1.13-1.36; I2 33%; $p < 0.0001$). Research conducted on 10 research articles found a significant relationship between ISR and family history of CHD (OR 1.27; CI 95% 1.02-1.58; I2 0%; $p = 0.03$). Meanwhile, research between ISR and dyslipidemia stated that there was no significant relationship between the two (OR 1.12; CI 95% 0.89-1.41; I2 71%; $p = 0.33$) (Figure 2).



Diabetes Mellitus



Smoking






Figure 2. Forest plot of the relationship between patient characteristics and ISR incidence

Table 2. Angiography characteristics


No	Outcomes	No of Studies	Type of TE	TE (95% CI)	P	I ²	P for I ²
1.	Lesion at LAD	21	OR	1.20 (1.07, 1.35)	0.002	39%	0.04
2.	Lesion at LCX	19	OR	1.17 (1.02, 1.34)	0.02	47%	0.01
3.	Lesion at RCA	21	OR	1.17 (1.04, 1.31)	0.008	31%	0.09
4.	Stent Diameter	13	MD	-0.12 (-0.22, -0.03)	0.009	94%	<0.00001
5.	Stent Length	13	MD	3.61 (1.81, 5.42)	<0.0001	93%	<0.00001

LAD is a lesion location that shows a significant correlation with the incidence of ISR (OR 1.20; 95% 1.07-1.35; I² 39%; p= 0.002). Apart from that, lesions located in the LCX also

have a significant relationship with the incidence of ISR (OR 1.17; 95% 1.02-1.34, I² 47%; p = 0.02). Lesions in the RCA were significantly correlated with the incidence of ISR (OR 1.17;

95% 1.04-1.31; I2 31%; p = 0.008). On the other hand, we have found that ISR is more likely to occur in patients with small stent diameters. The research we conducted on 13 articles stated that there was a significant relationship between stent diameter and ISR (MD -0.12; 95% CI -0.22,

-0.03; I2 94%; p 0.009). The research we have conducted in 13 articles states that there is a significant relationship between stent length and the incidence of ISR (MD 3.61; 95% CI 1.81-5.42; I2 93%; p <0.0001) (Figure 3).






Figure 3. Forest plot of the relationship between angiography characteristics and ISR incidence


Blood Parameters

Table 3. Blood parameters

No	Outcomes	No of Studies	Type of TE	TE (95% CI)	P	I ²	P for I ²
1.	Platelet Count	8	MD	-6.07 (-25.52, 13.38)	0.54	97%	<0.00001
2.	NLR	4	MD	0.46 (-0.51, 1.44)	0.35	96%	<0.00001
3.	RDW	6	MD	0.48 (0.09, 0.87)	0.02	91%	<0.00001
4.	Creatinine	8	MD	0.20 (-0.12, 0.52)	0.22	78%	<0.0001

Based on research that has been conducted from 8 articles, it is stated that there is no significant relationship between platelet count and the incidence of ISR (MD -6.07; CI 95% -25.52-13.38; I2 97%; p=0.54). In addition, research conducted on the Neutrophil Lymphocyte Ratio stated that there was no significant relationship with the incidence of ISR (MD 0.46; CI 95%

-0.51-1.44; I2 96%; p=0.35). Meanwhile, research on red cell distribution width (RDW) stated that there was a significant relationship with the incidence of ISR (MD 0.48; CI 95% 0.09-0.87; I2 91%; p=0.02). Creatinine did not have a significant relationship with the incidence of ISR (MD 0.20; CI 95% -0.12-0.52; I2 78%; p=0.22) (Figure 4).






Figure 4. Forest plot of the relationship between blood parameters and ISR incidence

DISCUSSION

Hypertension is a predisposing factor for coronary artery disease. High or fluctuating blood pressure causes acceleration of blood shear force on the vessel wall, therefore damaging the endothelial cells lining and stimulating restenosis.^{15,32} So, patients who underwent PCI are advised to strictly control their blood pressure to avoid restenosis. Both hypertension and diabetes mellitus complicate vascular lesions and unstable endothelial function.³³ During PCI intervention, coronary intimal tear or dissection tends to occur and promotes platelet adhesion.³⁴ Additionally, blood glucose may directly disrupt coronary endothelial cells, thus promoting ISR occurrence.³⁵ Unstable glucose metabolism activates an inflammation cascade in the endothelial wall, which is a predisposing factor for plaque formation. Inadequate blood glucose control following the PCI procedure will aggravate protein glycosylation and oxidation processes, thus stimulating ISR.³⁶ Moreover, cigarette smoking is closely related to the development and progression of coronary arterial disease. Our study reported a significant correlation between (OR 1.24; 95% CI 1.13-1.36; I² 33%; p < 0.0001). This result is coherent with the study by Huang *et al.*, which reported a microstructural change of the coronary artery after stenting in smoking vs non-smoking patients. Patients with persistent smoking demonstrated increased neointimal coverage, while smoking cessation retarded neointimal hyperplasia process.³⁷ This phenomenon is expected due to the nature of nicotine in cigarettes, which has been proven to stimulate

proliferation and migration of endothelial cells, therefore accelerating intimal hyperplasia.^{38,39} Family history may provoke ISR due to differences in immune response and genetic factors.⁴⁰ This study states that a family history of CAD has a significant effect on the incidence of ISR. This is in contrast to research conducted by Cheng *et al.*, which stated that family history of CAD was not significantly related to the incidence of ISR (p > 0.05).⁵ Dyslipidemia may also predispose to ISR, because, in particular, high LDL-C stimulates inflammation, damages endothelial cells, and promotes deposition of cholesterol in the blood vessel wall.⁴⁰

LAD is the lesion location that demonstrated significant correlation with ISR incidence (OR 1.20; 95% 1.07-1.35; I² 39%; p = 0.002). This result is similar to the previous studies, which also imply that the most common site of restenosis is the lesion in the LAD.^{41,42} Originally, bypass grafting was determined as superior compared to PCI in the LAD stenosis, because a significantly higher incidence of restenosis and revascularization was found in PCI compared to grafting.⁴³⁻⁴⁵ However, the start of DES has dramatically reduced the incidence of restenosis in LAD.⁴⁶ But still, with the treatment of PCI using DES, the ISR event was found to occur mostly in LAD lesions. In a study conducted by,⁹ stated that the incidence of ISR in ACS patients after successful PCI during angiographic follow-up of more than 2 years. The average time from stent placement to the occurrence of ISR was 32.8 months, and ISR tended to occur in LAD and LCX. Several other studies have shown that stent length is an important determinant of

ISR. Our study found a significant correlation between stent length and ISR incidence (MD 3.61; 95% CI 1.81-5.42; I2 93%; $p < 0.0001$). It shows that patients with longer stent lengths are more likely to experience ISR. Previous studies have shown similar results, where stent length is described as an important risk factor for ISR.⁴⁷ Research conducted by Hong et al. found that stent length (>40 mm) was an independent predictor of the development of ISR.⁴⁸ Mauri et al.⁴⁹ stated that each 10 mm increase of stent length was associated with an absolute increase of 7.7% stenosis diameter ($p < 0.0001$).⁴⁹ On the other hand, we found that ISR was more likely to occur in patients with small stent diameter, however, this correlation is not significant (MD -0.12; 95% CI -0.22, -0.03; I2 94%; $p = 0.009$). HORIZONS-AMI study reported that vascular caliber ≤ 3 mm increased ISR significantly.⁵⁰

The NLR (neutrophil count divided by lymphocyte count) is a potential biomarker of inflammation. Neutrophils play a major role in endothelial injury and platelet aggregation in acute coronary events. Lymphocytes represent the immunomodulatory response. Moreover, low lymphocyte counts in patients with CAD reflect the physiological stress of cortisol and correlate with a worse prognosis.⁵¹ NLR is an effective biomarker of systemic inflammation and is considered a predictor for the prognosis of different cardiovascular diseases, especially for CAD. CHD patients with high NLR have the potential for unstable plaque and inflammatory conditions.⁵² In a recent study, NLR was independently associated with early ISR after stent implantation in patients with femoropopliteal CTO.⁵³ The study conducted by Turak et al investigated the relationship of NLR before PCI and found that the NLR value predicted a higher incidence of ISR in ACS patients⁵⁴

Red blood cell distribution width (RDW) is a parameter that reflects the size of red blood cells. An increase in RDW indicates a greater heterogeneity of red blood cells in the peripheral blood.⁵⁵ Red cell distribution width is a measurement of the variability and size of erythrocytes. By deforming the red cell membrane, Inflammation may induce changes in red blood cell maturation, leading to increased

RDW.⁵⁶ In a recent study, an increased RDW predicted BMS restenosis, suggesting potential as a useful screening tool to stratify patients by higher or lower risk of ISR.⁵⁷ The mechanisms underlying the relationship between RDW restenosis and DES remain unclear. In this study, it was stated that RDW had a significant relationship with the incidence of ISR. This is different from research conducted by which stated that although RDW was higher in the ISR group, it did not show significance in multivariate analysis.³¹

Creatinine is a product of the hydrolysis reaction of phosphocreatine that occurs in muscles, which occurs with a fairly constant rhythm. A large amount of creatinine contained in the blood circulation will be filtered out with the urine, and not reabsorbed into the blood. Research conducted has found that serum creatinine in the ISR group was higher than in the non-ISR group, indicating that serum creatinine may be correlated with the occurrence of PCHD.²⁶ Creatinine is considered an indicator that can reflect kidney function. Research by Okada⁵⁸ found that serum creatinine was closely related to ISR in CHD patients.

Limitation the Study

Finally, this systematic review and meta-analysis have several limitations. First, the included studies were predominantly observational. Second, the small sample size makes the trial underpowered to detect small differences in some risk factors, such as hyperlipidemia, platelet count, and NLR. At last, further well-powered studies with more extensive adjustment of confounders are warranted to address some limitations of our current meta-analysis.

CONCLUSION

From our study, we found that diabetes mellitus and smoking are associated with the incidence of ISR in DES. In addition, as the angiography characteristics, stent lesion at LAD, RCA, and stent length may contribute to ISR in DES. By identifying the risk factors of ISR in DES, cardiologists may modify the attributable factors. Thus,

ISR in DES could be prevented. Further studies need to be conducted to explain the mechanism behind each risk factor in contributing to the event of ISR.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

REFERENCES

1. D.-M. Alexandrescu, et al. Risk factors associated with intra-stent restenosis after percutaneous coronary intervention. *Exp. Ther. Med.*. 2021;22(4)1–7. doi: 10.3892/etm.2021.10575.
2. Ochijewicz D, Tomaniak M, Opolski G, Kochman J. Inflammation as a determinant of healing response after coronary stent implantation. *Int. J. Cardiovasc. Imaging*. 2021;37(3):791–801 [Online]. Available: <https://doi.org/10.1007/s10554-020-02073-3>
3. Stolker JM, et al. Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. *Circ. Cardiovasc. Interv.* 2012;5(6):772–82 [Online]. Available: <https://doi.org/10.1161/CIRCINTERVENTIONS.111.967802>
4. Canbolat IP, Arat-özkan A. Predictors of in-stent restenosis in patients undergoing percutaneous coronary intervention Perkütan koroner girişim geçiren hastalarda stent-içi restenozun öngörücüleri. *J. Med.* 2019;5(2):87–90. doi: 10.5606/fng.btd.2019.015.
5. Cheng G, et al. Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease: A clinical trial based on 1-year follow-up. *Med. Sci. Monit.* 2019;25:240–7. doi: 10.12659/MSM.908692.
6. Feng Q, Zhao Y, Wang H, Zhao J, Wang X, Shi J. A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients. *Front. Cardiovasc. Med.* 2022;9(August):1–10. doi: 10.3389/fcvm.2022.857922.
7. Jiang Z, et al. Random forest vs. Logistic regression: predicting angiographic in - stent restenosis after second - generation drug - eluting stent implantation. *PLoS One*. 2022;17(5):1–13. doi: 10.1371/journal.pone.0268757.
8. Jing XD, Wei XM, Deng SB, Du JL, Liu YJ, She Q. The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis. *Clin. Chim. Acta.* 2015;446:248–52. doi: 10.1016/j.cca.2015.04.038.
9. M. Li, J. Hou, X. Gu, R. Weng, Z. Zhong, S. Liu, Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China. *Eur. J. Med. Res.* 2022;27(1):1–7. doi: 10.1186/s40001-022-00640-z.
10. Y. Luo, et al. Prognostic role of fasting remnant cholesterol with in-stent restenosis after drug-eluting stent implantation. *Int. J. Gen. Med.* 2022;15(Feb):1733–42. doi: 10.2147/IJGM.S348148.
11. D. Nakamura, et al. Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis. *Euro Intervention*. 2021;17(6):489–96. doi: 10.4244/EIJ-D-20-00539.
12. Z. Qin, et al. Elevated levels of very low-density lipoprotein cholesterol independently associated with in-stent restenosis in diabetic patients after drug-eluting stent implantation. *Chin. Med. J. (Engl)*. 2017;130(19):2326–32. doi: 10.4103/0366-6999.213575.
13. Song T, et al. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI. *BMC Cardiovasc. Disord.* 2021;21(1)1–10. doi: 10.1186/s12872-020-01839-w.
14. Tocci G, et al. Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis. *Am. J. Hypertens.* 2016;29(4):509–18. doi: 10.1093/ajh/hpv131.
15. Wang P, Qiao H, Wang RJ, Hou R, Guo J. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do. *BMC Cardiovasc. Disord.* 2020;20(1):1–6. doi: 10.1186/s12872-020-01798-2.
16. Xi H, et al. Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease. *Front. Cardiovasc. Med.* 2023;10(March)1–11. doi: 10.3389/fcvm.2023.1117915.
17. Zhao J, Wang X, Wang H, Zhao Y, Fu X. Occurrence and predictive factors of restenosis in coronary heart disease patients underwent sirolimus-eluting stent implantation. *Ir. J. Med. Sci.* 2020;189(3):907–15. doi: 10.1007/s11845-020-02176-9.
18. Zhao SG. CHA2DS2-Vasc score and CHA2DS2-Vasc-HS score are poor predictors of in-stent restenosis among patients with coronary drug-eluting stents. *J. Int. Med. Res.* 2019;47(6):2533–44. doi: 10.1177/0300060519841836.
19. Zhao K, Li YJ, Gao S. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting. *Coron. Artery Dis.* 2015;26(3):220–4. doi: 10.1097/MCA.0000000000000221.
20. Wu Y, Fu X. Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation. *J. Clin. Lab. Anal.*

- 2019;33(2):1–13. doi: 10.1002/jcla.22666.
21. Wang JL, et al. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. *J. Geriatr. Cardiol.* 2018;15(2):137–45 [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895953/>
 22. Zhou J, Chai D, Dai Y, Wang A, Yan T, Lu S. Predictive value analysis of in-stent restenosis within three years in older acute coronary syndrome patients: a two-center retrospective study. *Clin. Appl. Thromb.* 2022;289(58):1–9. doi: 10.1177/10760296221107888.
 23. Zhu Y, et al. Atherogenic index of plasma and the risk of in-stent restenosis in patients with acute coronary syndrome beyond the traditional risk factors. *J. Arterioscler. Thromb.* 2022;29(8):1226–35. doi: 10.5551/jat.63136.
 24. Zhang L, et al. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study. *BMC Cardiovasc. Disord.* 2021;21(1):1–11. doi: 10.1186/s12872-021-02245-6.
 25. Zeng MY, Yan XW, Wu W. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis. *BMC Cardiovasc. Disord.* 2021;21(1):1–9. doi: 10.1186/s12872-021-02259-0.
 26. Chen BW, et al. Analysis of the correlation between the ratio of monocytes to high-density lipoprotein cholesterol and in-stent restenosis in patients with premature coronary heart disease. *Clin. Appl. Thromb.* 2022;28:1–9. doi: 10.1177/10760296221079334.
 27. Gabbasov Z, et al. Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease. *Wien. Klin. Wochenschr.* 2016;(128):23–4, 898–905. doi: 10.1007/s00508-016-1074-x.
 28. Nan J, et al. The predictive value of monocyte count to high-density lipoprotein cholesterol ratio in restenosis after drug-eluting stent implantation. *Int. J. Gen. Med.* 2020;13:1255–63. doi: 10.2147/IJGM.S275202.
 29. Qian H, et al. Red cell distribution width in coronary heart disease: prediction of restenosis and its relationship with inflammatory markers and lipids. *Postgrad. Med. J.* 2018;94(1115):489–94. doi: 10.1136/postgradmedj-2018-135806.
 30. Tanindi A, Ekici B, Töre HF. Do pre-procedural laboratory parameters predict drug-eluting stent restenosis? *Turk Kardiyol. Dern. Ars.* 2015;43(5):457–64. doi: 10.5543/tkda.2015.48275.
 31. Li C, et al. Evaluation of preprocedural laboratory parameters as predictors of drug-eluting stent restenosis in coronary chronic total occlusion lesions. *Angiology.* 2019;70(3):272–8. doi: 10.1177/0003319717752245.
 32. Holmberg J, et al. Loss of vascular myogenic tone in mir-143/145 knockout mice is associated with hypertension-induced vascular lesions in small mesenteric arteries. *Arterioscler. Thromb. Vasc. Biol.*, 2018;38(2):414–24 [Online]. Available: <https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.117.310499>
 33. Geraldles R, et al. Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. *J. Neurol. Neurosurg. Psychiatry.* 2020;91(4):388–91 [Online]. Available: <https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.117.310499>
 34. Maor GS, Faden MS, Brown R. Prevalence, risk factors and pregnancy outcomes of women with vascular brain lesions in pregnancy. *Arch. Gynecol. Obstet.* 2020;301(3):665–70 [Online]. Available: <https://doi.org/10.1007/s00404-020-05451-3>
 35. Ferraro RA, et al. Non-obstructive high-risk plaques increase the risk of future culprit lesions comparable to obstructive plaques without high-risk features: The ICONIC study. *Eur. Heart J. Cardiovasc. Imaging.* 2020;21(9):973–80 [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/32535636/>
 36. Song B, Kim D, Nguyen NH, Roy S. Inhibition of diabetes-induced lysyl oxidase overexpression prevents retinal vascular lesions associated with diabetic retinopathy. *Investig. Ophthalmol. Vis. Sci.* 2018;59(15):5965–72 [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295938/>
 37. Huang X, et al. Impact of cigarette smoking and smoking cessation on stent changes as determined by optical coherence tomography after sirolimus stent implantation. *Am. J. Cardiol.* 2017;120(8):1279–84, 2017 [Online]. Available: <https://doi.org/10.1016/j.amjcard.2017.07.011>
 38. Villablanca AC. Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro. *J. Appl. Physiol.* 1998;84(6):2089–8 [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/9609804/>
 39. Hamasaki, et al. Effect of nicotine on the intimal hyperplasia after endothelial removal of the rabbit carotid artery. *Gen. Pharmacol.* 1997;28(5):653–9 [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/9184797/>
 40. Mehta A, et al. Lipoprotein(a) and family history predict cardiovascular disease risk. *J. Am. Coll. Cardiol.* 2020;76(7):781–93 [Online]. Available: <https://doi.org/10.1016/j.jacc.2020.06.040>
 41. Moreno R, et al. Long-term outcome of patients with proximal left anterior descending coronary artery in-stent restenosis treated with a second percutaneous procedure. *J. Invasive Cardiol.* 2005;17(4):218–21 [Online]. Available: <https://onlinelibrary.wiley.com/doi/full/10.1002/ccd.1098>
 42. Guardado JH, et al. Proximal left anterior descending coronary artery revascularization with drug-eluting stents. *Arq. Bras. Cardiol.* 2007;88(2):137–43 [Online]. Available: <https://doi.org/10.1590/S0066-782X2007000200005>
 43. Rodriguez A, et al. Coronary stenting versus coronary

- bypass surgery in patients with multiple vessel disease and significant proximal lad stenosis: Results from the ERACI II study. *Heart*. 2003;89(2):184–8 [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767529/>
44. Henderson R. A, et al. Long-term results of RITA-1 trial: Clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. *Lancet*. 1998;352(9138):1419–25 [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/9807988/>
 45. Design S. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. *N. Engl. J. Med.* 2001;344(15):1117–24 [Online]. Available: <https://doi.org/10.1056/nejm200104123441502>
 46. Sawhney N, et al. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. *Circulation*. 2004;110(4):374–9 [Online]. Available: <https://www.ahajournals.org/doi/10.1161/01.CIR.0000136580.34604.B8>
 47. Choi IJ, et al. Impact of the stent length on long-term clinical outcomes following newer-generation drug-eluting stent implantation. *Am. J. Cardiol.* 2014;113(3):457–64 [Online]. Available: <http://dx.doi.org/10.1016/j.amjcard.2013.10.029>
 48. Hong MK, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. *Eur. Heart J.* 2006;27(11):1305–10 [Online]. Available: <https://doi.org/10.1093/eurheartj/ehi882>
 49. Mauri L, et al. Effects of stent length and lesion length on coronary restenosis. *Am. J. Cardiol.* 2004;93(11): 1340–6 [Online]. Available: [https://www.ajconline.org/article/S0002-9149\(04\)00275-9/fulltext](https://www.ajconline.org/article/S0002-9149(04)00275-9/fulltext)
 50. Stone GW, et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the horizons-ami (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. *J. Am. Coll. Cardiol.* 2010;56(19):1597–604 [Online]. Available: <https://doi.org/10.1016/j.jacc.2010.08.608>
 51. Wang Z, Liu C, Fang H. Blood cell parameters and predicting coronary in-stent restenosis. *Angiology*. 2019;70(8):711–8 [Online]. Available: <https://doi.org/10.1177/0003319719830495>
 52. Choi YH, Hong YJ, Ahn Y, Park IH, Jeong MH. Relationship between neutrophil-to-lymphocyte ratio and plaque components in patients with coronary artery disease: virtual histology intravascular ultrasound analysis. *J. Korean Med. Sci.* 2014;29(7):950–6 [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/26535014/>
 53. Chang Z, Zheng J, Liu Z, Guo Q. The relationship between the neutrophil-lymphocyte ratio and in-stent restenosis in patients with femoropopliteal chronic total occlusions. *Angiology*. 2018;69(2):177–82 [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/28635304/>
 54. Turak O, et al. Usefulness of the neutrophil to lymphocyte ratio to predict bare metal stent restenosis. *Am. J. Cardiol.* 2012;110(10):1405–10 [Online]. Available: <http://dx.doi.org/10.1016/j.amjcard.2012.07.003>
 55. Demirkol S, et al. Assessment of the relationship between red cell distribution width and cardiac syndrome X. *Kardiol. Pol.* 2013;71(5):480–4 [Online]. Available: https://journals.viamedica.pl/kardiologia_polska/article/view/77451
 56. Weiss G, Goodnough LT. Anemia of chronic disease. *N. Engl. J. Med.* 2019;352(10):1011–23 [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/15758012/>
 57. Yildiz A, Tekiner F, Karakurt A, Sirin G, Duman D. Preprocedural red blood cell distribution width predicts bare metal stent restenosis. *Coron. Artery Dis.* 2014;25(6):469–73 [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/15758012/>
 58. Okada T, Yuge M, Kawaguchi T, Hojo Y. The urinary albumin-to-creatinine ratio is a potential predictor of target lesion revascularization after percutaneous coronary intervention with coronary stents. *Int. Heart J.* 2014;55(5):409–15 [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/25088583/>